Author:
Zhao Shen,Wang Dong,Zhao Hongyun,Gong Jifang,Zhang Jian,Fang Wenfeng,Ma Fei,Xu Binghe,Li Jin,Hu Xichun,Ba Yi,Chen Xiaoyuan,Yang Zhimin,Shen Lin,Jiang Jianhua,Zhang Li
Subject
Cancer Research,Cell Biology,Oncology
Reference8 articles.
1. BIO QLS Advisors and Ltd, I.U. (2020). Clinical Development Success Rates and Contributing Factors 2011-2020. Access on Nov 2021: https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020.
2. National Medical Products Administration of China (NMPA) (2021). Annual report on registration clincial trials for investigataional new drugs in China (2020) Access on Nov 2021: https://www.cde.org.cn/main/news/viewInfoCommon/d670723dd2f646722097b03cf005e052.
3. Clinical development success rates for investigational drugs;Hay;Nat. Biotechnol.,2014
4. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review;Li;Lancet Oncol.,2019
5. US Food and Drug Administration (2014). Division Director Summary Review: Keytruda injection/pembrolizumab. Application No. 125514Orig1s000. Access on September 4, 2014: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000SumR.pdf.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献